 | • レポートコード：PMR2201A047 • 出版社/出版日：Persistence Market Research / 2021年10月25日 • レポート形態：英文、PDF、220ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、世界の抗体受託製造市場について調査し、エグゼクティブサマリー、市場概要、主要インクルージョン、主要成功要因、市場背景、新型コロナウイルス感染症の影響分析、市場需要分析/予測、製品別（モノクローナル抗体、抗体フラグメントン、ポリクローナル抗体）分析、発現別（哺乳類、微生物）分析、企業規模別（小型、中型、大型、超大型）分析、運用別（前臨床、臨床、商業）分析、地域別分析、主要国分析、市場構造分析、競争分析、仮定、調査手法などを掲載しています。 ・エグゼクティブサマリー ・市場概要 ・主要インクルージョン ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症の影響分析 ・市場需要分析/予測 ・世界の抗体受託製造市場規模：製品別（モノクローナル抗体、抗体フラグメントン、ポリクローナル抗体） ・世界の抗体受託製造市場規模：発現別（哺乳類、微生物） ・世界の抗体受託製造市場規模：企業規模別（小型、中型、大型、超大型） ・世界の抗体受託製造市場規模：運用別（前臨床、臨床、商業） ・世界の抗体受託製造市場規模：地域別 ・主要国分析 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Antibodies Contract Manufacturing Market- Scope of Report
The latest publication by Persistence Market Research on the antibodies contract manufacturing market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2021-2031.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for antibodies contract manufacturing market and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the antibodies contract manufacturing market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the antibodies contract manufacturing market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the antibodies contract manufacturing market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the antibodies contract manufacturing market offers information divided into five important segments – product, expression system, company size, scale of operation, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Monoclonal Antibodies
Antibody Fragments
Polyclonal Antibodies
Expression System
Mammalian
Microbial
Bacteria
Yeast
Company Size
Small
Mid-sized
Large
Very large
Scale of Operation
Preclinical
Clinical
Commercial
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for antibodies contract manufacturing market over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the antibodies contract manufacturing industry avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the antibodies contract manufacturing market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research’s projections on the growth prospects of the antibodies contract manufacturing market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Key Market Trends
1.3. Market Analysis & Recommendation
2. Market Overview
2.1 Market Coverage/Taxonomy
2.2 Market Definition/Scope
2.3 Inclusions/Exclusions
3. Key Inclusions
3.1. Key Trends Impacting the Market
3.2. Product Innovation/ Development Trends
4. Key Success Factors
4.1. Product Adoption/Usage Analysis
4.2. List of Trading Companies in China and India
4.3. List of Local Manufacturers and their Distribution Strategy/Locations
4.4. Key Regulatory Scenario
4.5. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Healthcare Expenditure Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Increasing number of healthcare facilities
5.2.2. Emergence of new infectious diseases
5.2.3. Rise in disposable income
5.2.4. Key players historic growth
5.2.5. New product approval/launches
5.2.6. Growing popularity of healthcare check-ups
5.2.7. Product Adoption
5.2.8. Rise in Prevalence of chronic and lifestyle disease
5.2.9. Key Strategic developments
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities
6. COVID-19 Crisis Impact Analysis
6.1.1. Current COVID-19 perspective and Probable Impact
6.1.2. Current GDP Projections and Probable Impact
6.1.3. COVID-19 Crisis Analysis- Overview
6.1.4. COVID-19 Crisis Impact –Global
6.1.5. COVID-19 Crisis Impact on Antibodies Contract Manufacturing Market
7. Global Antibodies Contract Manufacturing Market Demand Value (Size US$ Mn) Analysis, By Product,2016-2020 and Forecast 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis. 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Antibodies Contract Manufacturing Market and Volume Analysis 2016-2020 and Forecast, 2021-2031, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2016-2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2021 – 2031
8.3.1. Monoclonal Antibodies
8.3.2. Antibody Fragments
8.3.3. Polyclonal Antibodies
8.4. Market Attractiveness Analysis By Product
9. Global Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Expression System, 2016-2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Expression System, 2021-2031
9.3.1. Mammalian
9.3.2. Microbial
9.3.2.1. Bacteria
9.3.2.2. Yeast
9.4 Market Attractiveness Analysis By Expression System
10. Global Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031, By Company Size
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Company Size, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Company Size, 2021-2031
10.3.1. Small
10.3.2. Mid-Sized
10.3.3. Large
10.3.4. Very large
10.4. Market Attractiveness Analysis By Company Size
11. Global Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031, By Scale of Operation
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Scale of Operation, 2016-2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Scale of Operation, 2021-2031
11.3.1. Preclinical
11.3.2. Clinical
11.3.3. Commercial
11.4 Market Attractiveness Analysis By Company Size
12. Global Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. U. S.
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Expression System
13.3.4. By Company Size
13.3.5. By Scale of Operation
13.4. Market Attractiveness Analysis
13.5. Key Market Participants – Intensity Mapping
13.6. Drivers and Restraints – Impact Analysis
14. Latin America Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Expression System
14.3.4. By Company Size
14.3.5. By Scale of Operation
14.4. Market Attractiveness Analysis
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
15. Europe Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U. K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By Expression System
15.3.4. By Company Size
15.3.5. By Scale of Operation
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. South Asia Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
16.1 Introduction
16.2 Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
16.3 Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Product
16.3.3. By Expression System
16.3.4. By Company Size
16.3.5. By Scale of Operation
16.4. Market Attractiveness Analysis
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
17. East Asia Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
17.1 Introduction
17.2 Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
17.3 Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Expression System
17.3.4. By Company Size
17.3.5. By Scale of Operation
17.4. Market Attractiveness Analysis
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
18. Oceania Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Expression System
18.3.4. By Company Size
18.3.5. By Scale of Operation
18.4. Market Attractiveness Analysis
18.5. Key Market Participants – Intensity Mapping
18.6. Drivers and Restraints – Impact Analysis
19. Middle East and Africa Antibodies Contract Manufacturing Market Analysis 2016-2020 and Forecast, 2021-2031
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. South Africa
19.3.1.3. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Expression System
19.3.4. By Company Size
19.3.5. By Scale of Operation
19.4. Market Attractiveness Analysis
19.5. Key Market Participants-Intensity Mapping
19.6. Drivers and Restraints-Impact Analysis
20. Key and Emerging Countries Antibodies Contract Manufacturing Market Analysis 2021 & 2031
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. U. S. Antibodies Contract Manufacturing Market Analysis
20.2.1. By Product
20.2.2. By Expression System
20.2.3. By Company Size
20.2.4. By Scale of Operation
20.3. Canada Antibodies Contract Manufacturing Market Analysis
20.3.1. By Product
20.3.2. By Expression System
20.3.3. By Company Size
20.3.4. By Scale of Operation
20.4. Mexico Antibodies Contract Manufacturing Market Analysis
20.4.1. By Product
20.4.2. By Expression System
20.4.3. By Company Size
20.4.4. By Scale of Operation
20.5. Brazil Antibodies Contract Manufacturing Market Analysis
20.5.1. By Product
20.5.2. By Expression System
20.5.3. By Company Size
20.5.4. By Scale of Operation
20.6. U. K. Antibodies Contract Manufacturing Market Analysis
20.6.1. By Product
20.6.2. By Expression System
20.6.3. By Company Size
20.6.4. By Scale of Operation
20.7. Germany Antibodies Contract Manufacturing Market Analysis
20.7.1. By Product
20.7.2. By Expression System
20.7.3. By Company Size
20.7.4. By Scale of Operation
20.8. France Antibodies Contract Manufacturing Market Analysis
20.8.1. By Product
20.8.2. By Expression System
20.8.3. By Company Size
20.8.4. By Scale of Operation
20.9. Italy Antibodies Contract Manufacturing Market Analysis
20.9.1. By Product
20.9.2. By Expression System
20.9.3. By Company Size
20.9.4. By Scale of Operation
20.10. Spain Antibodies Contract Manufacturing Market Analysis
20.10.1. By Product
20.10.2. By Expression System
20.10.3. By Company Size
20.10.4. By Scale of Operation
20.11. BENELUX Antibodies Contract Manufacturing Market Analysis
20.11.1. By Product
20.11.2. By Expression System
20.11.3. By Company Size
20.11.4. By Scale of Operation
20.12. Russia Antibodies Contract Manufacturing Market Analysis
20.12.1. By Product
20.12.2. By Expression System
20.12.3. By Company Size
20.12.4. By Scale of Operation
20.13. China Antibodies Contract Manufacturing Market Analysis
20.13.1. By Product
20.13.2. By Expression System
20.13.3. By Company Size
20.13.4. By Scale of Operation
20.14. Japan Antibodies Contract Manufacturing Market Analysis
20.14.1. By Product
20.14.2. By Expression System
20.14.3. By Company Size
20.14.4. By Scale of Operation
20.15. South Korea Antibodies Contract Manufacturing Market Analysis
20.15.1. By Product
20.15.2. By Expression System
20.15.3. By Company Size
20.15.4. By Scale of Operation
20.16. India Antibodies Contract Manufacturing Market Analysis
20.16.1. By Product
20.16.2. By Expression System
20.16.3. By Company Size
20.16.4. By Scale of Operation
20.17. ASEAN Antibodies Contract Manufacturing Market Analysis
20.17.1. By Product
20.17.2. By Expression System
20.17.3. By Company Size
20.17.4. By Scale of Operation
20.18. Australia Antibodies Contract Manufacturing Market Analysis
20.18.1. By Product
20.18.2. By Expression System
20.18.3. By Company Size
20.18.4. By Scale of Operation
20.19. New Zealand Antibodies Contract Manufacturing Market Analysis
20.19.1. By Product
20.19.2. By Expression System
20.19.3. By Company Size
20.19.4. By Scale of Operation
20.20. GCC Countries Antibodies Contract Manufacturing Market Analysis
20.20.1. By Product
20.20.2. By Expression System
20.20.3. By Company Size
20.20.4. By Scale of Operation
20.21. Turkey Antibodies Contract Manufacturing Market Analysis
20.21.1. By Product
20.21.2. By Expression System
20.21.3. By Company Size
20.21.4. By Scale of Operation
20.22. South Africa Antibodies Contract Manufacturing Market Analysis
20.22.1. By Product
20.22.2. By Expression System
20.22.3. By Company Size
20.22.4. By Scale of Operation
21. Market Structure Analysis
21.1. Market Analysis By Tier of Companies
21.2. Market Share Analysis By Key Players
22. Competition Analysis
22.1.1. AMRI
22.1.1.1. Product Type Portfolio
22.1.1.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.1.1.2. Sales Footprint
22.1.1.1.3. Analyst commentary
22.1.2. AGC Biologics
22.1.2.1. Product Type Portfolio
22.1.2.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.2.1.2. Sales Footprint
22.1.2.1.3. Analyst commentary
22.1.3. Aldevron
22.1.3.1. Product Type Portfolio
22.1.3.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.3.1.2. Sales Footprint
22.1.3.1.3. Analyst commentary
22.1.4. Eurofins CDMO
22.1.4.1. Product Type Portfolio
22.1.4.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.4.1.2. Sales Footprint
22.1.4.1.3. Analyst commentary
22.1.5. Boehringer Ingelheim BioXcellence
22.1.5.1. Product Type Portfolio
22.1.5.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.5.1.2. Sales Footprint
22.1.5.1.3. Analyst commentary
22.1.6. FUJIFILM Diosynth Biotechnologies
22.1.6.1. Product Type Portfolio
22.1.6.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.6.1.2. Sales Footprint
22.1.6.1.3. Analyst commentary
22.1.7. Emergent BioSolutions
22.1.7.1. Product Type Portfolio
22.1.7.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.7.1.2. Sales Footprint
22.1.7.1.3. Analyst commentary
22.1.8. KBI Biopharma
22.1.8.1. Product Type Portfolio
22.1.8.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.8.1.2. Sales Footprint
22.1.8.1.3. Analyst commentary
22.1.9. Lonza
22.1.9.1. Product Type Portfolio
22.1.9.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.9.1.2. Sales Footprint
22.1.9.1.3. Analyst commentary
22.1.10. Novasep
22.1.10.1. Product Type Portfolio
22.1.10.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.10.1.2. Sales Footprint
22.1.10.1.3. Analyst commentary
22.1.11. Nitto Avecia Pharma Services
22.1.11.1. Product Type Portfolio
22.1.11.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.11.1.2. Sales Footprint
22.1.11.1.3. Analyst commentary
22.1.12. Pierre Fabre
22.1.12.1. Product Type Portfolio
22.1.12.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.12.1.2. Sales Footprint
22.1.12.1.3. Analyst commentary
22.1.13. Samsung BioLogics
22.1.13.1. Product Type Portfolio
22.1.13.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.13.1.2. Sales Footprint
22.1.13.1.3. Analyst commentary
22.1.14. Synthon
22.1.14.1. Product Type Portfolio
22.1.14.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.14.1.2. Sales Footprint
22.1.14.1.3. Analyst commentary
22.1.15. Thermo Fisher Scientific.
22.1.15.1. Product Type Portfolio
22.1.15.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.15.1.2. Sales Footprint
22.1.15.1.3. Analyst commentary
22.1.16. AbbVie, Inc.
22.1.16.1. Product Type Portfolio
22.1.16.1.1. Profitability by Market Segments (Drug Class/Distribution Channel/Region)
22.1.16.1.2. Sales Footprint
22.1.16.1.3. Analyst commentary
23. Assumptions & Acronyms
24. Research Methodology
Table 01: Global Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By ProductTable 02: Global Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 03: Global Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 04: Global Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 05: Global Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 06: Global Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region
Table 07: North America Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 08: North America Antibodies Contract Manufacturing Market Size (Usman) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 09: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 10: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 11: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 12: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 13: Latin America Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 14: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 15: North America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 16: Latin America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 17: Latin America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 18: Latin America Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 19: Europe Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 20: Europe Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 21: Europe Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 22: Europe Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 23: Europe Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 24: Europe Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 25: South Asia Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 26: South Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 27: South Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 28: South Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 29: South Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 30: South Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 31: East Asia Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 32: East Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 33: East Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 34: East Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 35: East Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 36: East Asia Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 37: Oceania Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 38: Oceania Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 39: Oceania Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 40: Oceania Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 41: Oceania Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 42: Oceania Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country
Table 43: MEA Antibodies Contract Manufacturing Market Volume (Mn ) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 44: MEA Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Product
Table 45: MEA Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Expression System
Table 46: MEA Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Company Size
Table 47: MEA Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Scale of Operation
Table 48: MEA Antibodies Contract Manufacturing Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country